High-dose intravenous immunoglobulin as a therapeutic option for deteriorating patients with coronavirus disease 2019

Open Forum Infectious Diseases

Volumn 7, Issue 3, 2020, Pages 1-6

  Cao, Wei ^a   Liu, Xiaosheng ^b   Bai, Tao ^c   Fan, Hongwei ^a   Hong, Ke ^c   Song, Hui ^c   Han, Yang ^a   Lin, Ling ^a   Ruan, Lianguo ^c   Li, Taisheng ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^b Tsinghua University   (China)

^c Jinyintan Hospital   (China)

Author keywords

Coronavirus disease 2019; High dose intravenous immunoglobulin; Immunomodulation; SARS CoV 2

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ASPARTATE AMINOTRANSFERASE; AZITHROMYCIN; BILIRUBIN; C REACTIVE PROTEIN; CREATINE KINASE; CREATININE; D DIMER; GAMMA GLUTAMYLTRANSFERASE; IMMUNOGLOBULIN; LACTATE DEHYDROGENASE; LOPINAVIR PLUS RITONAVIR; METHYLPREDNISOLONE; MOXIFLOXACIN; MYOGLOBIN; OSELTAMIVIR; TROPONIN; URIC ACID;

ADULT; ARTICLE; BLOOD PRESSURE; BREATHING RATE; CASE REPORT; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CORONAVIRUS DISEASE 2019; COUGHING; DETERIORATION; DRUG MEGADOSE; DYSPNEA; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FEVER; HUMAN; LEUKOCYTE COUNT; LEUKOPENIA; MALE; MIDDLE AGED; OXYGEN SATURATION; PLATELET COUNT; PLEURA THICKENING; PRIORITY JOURNAL; PROTHROMBIN TIME; REAL TIME REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2; SORE THROAT; THROAT CULTURE;

EID: 85083156986     PISSN: None     EISSN: 23288957     Source Type: Journal    
DOI: 10.1093/ofid/ofaa102     Document Type: Article

References (17)

1. Real-time updates: national outbreak map of new coronary virus pneumonia. Available at: Https://news.sina.cn/zt_d/yiqing0121. Accessed 12 March 2020.
2. National Health Commission of the People's Republic of China. Chinese recommendations for diagnosis and treatment of novel coronavirus (SARSCoV2) infection (pilot 4th version). Available at: Http://www.gov.cn/zhengce/zhengceku/2020-01/28/5472673/files/0f96c10cc09d4d36a6f9a9f0b42d972b.pdf. Accessed 12 March 2020.
3. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395:497-506.
4. Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. New Engl J Med 2020; 382:727-33.
5. Chung M, Bernheim A, Mei X, et al. CT imaging features of 2019 novel coronavirus (2019-nCoV). Radiology 2020; 295:202-07.
6. Patwa HS, Chaudhry V, Katzberg H, et al. Evidence-based guideline: Intravenous immunoglobulin in the treatment of neuromuscular disorders: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2012; 78:1009-15.
7. Godeau B, Caulier MT, Decuypere L, et al. Intravenous immunoglobulin for adults with autoimmune thrombocytopenic purpura: Results of a randomized trial comparing 0.5 and 1 g/kg b.w. Br J Haematol 1999; 107:716-9.
8. Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: Implications for virus origins and receptor binding. Lancet. 2020; 395:565-74.
9. Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor recognition by novel coronavirus from Wuhan: An analysis based on decade-long structural studies of SARS. J Virol. In press.
10. Gurwitz D. Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics. Drug Dev Res. In press.
11. Galeotti C, Kaveri SV, Bayry J. IVIG-mediated effector functions in autoimmune and inflammatory diseases. Int Immunol 2017; 29:491-8.
12. De Ranieri D, Fenny NS. Intravenous immunoglobulin in the treatment of primary immunodeficiency diseases. Pediatr Ann 2017; 46:e8-e12.
13. Hartung HP. Advances in the understanding of the mechanism of action of IVIg. J Neurol 2008; 255(Suppl 3):3-6.
14. Wiedeman AE, Santer DM, Yan W, et al. Contrasting mechanisms of interferon-α inhibition by intravenous immunoglobulin after induction by immune complexes versus Toll-like receptor agonists. Arthritis Rheum 2013; 65:2713-23.
15. Khanna N, Widmer AF, Decker M, et al. Respiratory syncytial virus infection in patients with hematological diseases: Single-center study and review of the literature. Clin Infect Dis 2008; 46:402-12.
16. Wang JT, Sheng WH, Fang CT, et al. Clinical manifestations, laboratory findings, and treatment outcomes of SARS patients. Emerg Infect Dis 2004; 10:818-24.
17. Arabi YM, Arifi AA, Balkhy HH, et al. Clinical course and outcomes of critically ill patients with Middle East respiratory syndrome coronavirus infection. Ann Intern Med 2014; 160:389-97.